Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 5/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303412 | 0.80 | HCRTR2 (0.32) | GRIK1GRIA2DRD2DRD4KDM4E | |
| SCHEMBL3391713 | 0.79 | GRIK1 (0.35) | GRIK1GRIA2APOBEC3AAPOBEC3GKDM4E | |
| SCHEMBL3391565 | 0.79 | GRIK1 (0.38) | GRIK1GRIA2 | |
| SCHEMBL3391198 | 0.78 | GRIK1 (0.46) | GRIK1GRIA2KDM4E | |
| SCHEMBL6484834 | 0.68 | TACR1 (0.41) | KDM4E | |
| SCHEMBL3305726 | 0.68 | ATM (0.41) | KDM4ETSHR | |
| SCHEMBL7171997 | 0.68 | CXCR4 (0.40) | KDM4E | |
| SCHEMBL6494432 | 0.67 | GRIK1 (0.44) | GRIK1GRIA2KDM4ETSHRHSD17B10 | |
| SCHEMBL3391628 | 0.67 | MEN1 (0.43) | GRIK1GRIA2DRD2DRD4KDM4E | |
| SCHEMBL6484163 | 0.67 | TSHR (0.38) | CHRNB4CHRNA3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | ARNOLD MACKLIN B | 2006-05-11 | — | — | US | disclosed |
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
| EP-1368032-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003024453-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | GRIK1 8/4885GRIA2 14/4885CHRNB4 345/4885 |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | GRIK1 8/4885GRIA2 14/4885CHRNB4 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.